Chonluten vs Bronchogen
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
ChonlutenAnti-Aging & Longevity
Bronchogen- Summary
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- Half-Life
- Short (minutes for the peptide); sustained gene-regulatory effects
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Admin Route
- SubQ, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 10 mg per day
- Frequency
- Daily for 10–30 days
- Daily for 10–30 days
- Key Benefits
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Side Effects
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Stacks With
- —
- —